Table 7.
Selected outcome measures by baseline QIDS-SR16 and treatment
| Treatment | Baseline QIDS-SR16 |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mild |
Moderate |
Severe |
Very severe |
||||||||||
| BUP-SR + ESCIT n=32 |
ESCIT + PBO n=26 |
VEN-XR + MIRT n=23 |
BUP-SR + ESCIT n=72 |
ESCIT + PBO n=94 |
VEN-XR + MIRT n=72 |
BUP-SR + ESCIT n=91 |
ESCIT + PBO n=80 |
VEN-XR + MIRT n=89 |
BUP-SR + ESCIT n=22 |
ESCIT + PBO n=18 |
VEN-XR + MIRT n=27 |
p- value* |
|
| % | % | % | % | % | % | % | % | % | % | % | % | ||
| Week 12 | |||||||||||||
| Early termination | 25.0 | 15.4 | 30.4 | 31.9 | 22.3 | 23.6 | 33.0 | 27.5 | 29.2 | 36.4 | 38.9 | 18.5 | 0.6327 |
| Last QIDS-SR16 <6 | 71.0 | 61.5 | 56.5 | 36.1 | 39.4 | 35.2 | 30.0 | 28.8 | 31.5 | 18.2 | 27.8 | 33.3 | 0.7915 |
| % QIDS-SR16 reduction >50% | 48.4 | 42.3 | 56.5 | 51.4 | 48.9 | 49.3 | 50.0 | 58.8 | 51.7 | 63.6 | 50.0 | 59.3 | 0.7724 |
| Week 28 | |||||||||||||
| Early termination | 37.5 | 30.8 | 39.1 | 36.1 | 34.0 | 38.9 | 40.7 | 33.8 | 38.2 | 36.4 | 50.0 | 29.6 | 0.7979 |
| Last QIDS-SR16 <6 | 68.8 | 76.9 | 60.9 | 43.7 | 44.7 | 45.1 | 41.6 | 41.8 | 31.5 | 36.4 | 22.2 | 42.3 | 0.5439 |
| % QIDS-SR16 reduction >50% | 53.1 | 65.4 | 60.9 | 54.9 | 57.4 | 62.0 | 58.4 | 59.5 | 47.2 | 77.3 | 61.1 | 76.9 | 0.3902 |
| Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | ||
| Week 12 | |||||||||||||
| Last QIDS-SR16 | 4.6 (3.4) | 5.6 (4.7) | 5.4 (4.4) | 7.2 (4.3) | 7.1 (4.1) | 7.5 (4.7) | 9.8 (5.8) | 9.1 (5.7) | 9.6 (6.1) | 10.0 (5.4) | 10.8 (7.2) | 9.6 (7.0) | 0.9273 |
| % QIDS-SR16 reduction | −32 (50.3) | −35 (46.4) | −38 (45.6) | −45 (32.1) | −47 (29.6) | −44 (33.5) | −46 (31.8) | −49 (31.6) | −46 (34.3) | −56 (21.8) | −51 (32.5) | −57 (31.5) | 0.9785 |
| Week 28 | |||||||||||||
| Last QIDS-SR16<6 | 4.3 (3.6) | 4.6 (4.3) | 5.1 (5.2) | 7.0 (4.8) | 6.6 (4.4) | 6.8 (4.5) | 8.5 (5.9) | 8.7 (6.0) | 10.1 (6.5) | 8.6 (5.6) | 10.3 (6.7) | 8.3 (6.4) | 0.8903 |
| % QIDS-SR16 reduction | −39 (50.0) | −47 (38.3) | −43 (51.5) | −47 (37.0) | −51 (31.8) | −49 (32.2) | −54 (31.8) | −52 (32.9) | −44 (35.5) | −62 (22.6) | −53 (31.2) | −63 (28.6) | 0.4937 |
*
p-value associated with the baseline QIDS-SR16 by treatment interaction term.
QIDS-SR16 categories: mild = 0–10, moderate = 11–15, severe = 16–20, very severe = 21–27.
Abbreviations: BUP-SR, Bupropion-sustained release; ESCIT, escitalopram; FIBSER, Frequency, intensity, and burden of side effects scale; MIRT, Mirtazapine; PBO, placebo; QIDS-SR16, 16 item quick inventory of depressive symptomatology – self-rated; VEN-XR, Venlafaxine-extended release.